ID   SNU-1746
AC   CVCL_5030
SY   SNU1746
DR   cancercelllines; CVCL_5030
DR   ColonAtlas; SNU1746
DR   Cosmic; 1322294
DR   GEO; GSM1448206
DR   IARC_TP53; 28483
DR   KCLB; 01746
DR   Wikidata; Q54955128
RX   PubMed=20176655;
RX   PubMed=25926053;
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Doubling time: 42 hours (PubMed=20176655).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=20176655; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr562fs*19 (c.1682_1683insA); Zygosity=Heterozygous (PubMed=20176655).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1429Ter (c.4285C>T); ClinVar=VCV000376063; Zygosity=Heterozygous (PubMed=20176655).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (PubMed=20176655).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20176655).
CC   Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Glu523Lys (c.1567G>A); Zygosity=Homozygous (PubMed=20176655).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20176655).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): KCLB=01746; PubMed=20176655; PubMed=25926053
ST   Amelogenin: X,Y
ST   CSF1PO: 7,9
ST   D13S317: 9
ST   D16S539: 9,14
ST   D18S51: 13,18
ST   D19S433: 13,17.2
ST   D21S11: 28,33
ST   D2S1338: 18,24
ST   D3S1358: 14,17
ST   D5S818: 11,12,13 (KCLB=01746)
ST   D5S818: 11,12,13,14 (PubMed=25926053)
ST   D5S818: 12,13 (PubMed=20176655)
ST   D7S820: 8,11
ST   D8S1179: 11
ST   FGA: 17,22
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 15,18 (KCLB=01746; PubMed=20176655)
ST   vWA: 18 (PubMed=25926053)
DI   NCIt; C7967; Colon signet ring cell adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 23
//
RX   PubMed=20176655; DOI=10.1093/carcin/bgq043;
RA   Ku J.-L., Shin Y.-K., Kim D.-W., Kim K.-H., Choi J.-S., Hong S.-H.,
RA   Jeon Y.-K., Kim S.-H., Kim H.-S., Park J.-H., Kim I.-J., Park J.-G.;
RT   "Establishment and characterization of 13 human colorectal carcinoma
RT   cell lines: mutations of genes and expressions of drug-sensitivity
RT   genes and cancer stem cell markers.";
RL   Carcinogenesis 31:1003-1009(2010).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//